CINECA IRIS Institutional Research Information System

CALCAGNO, Andrea
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 17.598
EU - Europa 10.044
AS - Asia 5.621
SA - Sud America 607
AF - Africa 379
OC - Oceania 134
Continente sconosciuto - Info sul continente non disponibili 24
Totale 34.407
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 17.220
IT - Italia 2.302
CN - Cina 2.034
SG - Singapore 1.743
DK - Danimarca 1.388
IE - Irlanda 1.006
DE - Germania 802
FR - Francia 749
SE - Svezia 745
GB - Regno Unito 552
FI - Finlandia 479
AT - Austria 374
BR - Brasile 357
UA - Ucraina 328
ID - Indonesia 281
KR - Corea 276
VN - Vietnam 263
IN - India 260
ES - Italia 242
CA - Canada 233
NL - Olanda 231
PL - Polonia 230
JP - Giappone 179
ZA - Sudafrica 134
AU - Australia 123
MX - Messico 114
RO - Romania 102
RU - Federazione Russa 100
HK - Hong Kong 97
BE - Belgio 92
TW - Taiwan 88
TH - Thailandia 85
CH - Svizzera 79
TR - Turchia 74
AR - Argentina 61
CL - Cile 55
PK - Pakistan 53
CO - Colombia 52
PE - Perù 52
CZ - Repubblica Ceca 45
IR - Iran 40
PT - Portogallo 39
GR - Grecia 35
UG - Uganda 32
PH - Filippine 29
NG - Nigeria 26
HU - Ungheria 22
EU - Europa 21
IL - Israele 21
EG - Egitto 18
ET - Etiopia 18
KE - Kenya 18
TZ - Tanzania 16
EC - Ecuador 14
NO - Norvegia 14
BG - Bulgaria 13
MY - Malesia 13
HR - Croazia 12
SA - Arabia Saudita 12
SK - Slovacchia (Repubblica Slovacca) 12
SN - Senegal 12
DZ - Algeria 11
NZ - Nuova Zelanda 11
AE - Emirati Arabi Uniti 10
MW - Malawi 10
UZ - Uzbekistan 10
ML - Mali 9
SD - Sudan 9
LT - Lituania 8
MU - Mauritius 8
TN - Tunisia 8
BO - Bolivia 7
GM - Gambi 7
JO - Giordania 7
LV - Lettonia 7
BY - Bielorussia 6
GH - Ghana 6
LU - Lussemburgo 6
RS - Serbia 6
CR - Costa Rica 5
IQ - Iraq 5
PA - Panama 5
CU - Cuba 4
DO - Repubblica Dominicana 4
EE - Estonia 4
GA - Gabon 4
GE - Georgia 4
GT - Guatemala 4
HN - Honduras 4
KZ - Kazakistan 4
MA - Marocco 4
MD - Moldavia 4
MZ - Mozambico 4
NA - Namibia 4
NP - Nepal 4
VE - Venezuela 4
AL - Albania 3
BH - Bahrain 3
CD - Congo 3
CM - Camerun 3
Totale 34.346
Salva come PNG Salva come JPEG
Città #
Ann Arbor 2.899
Chandler 1.715
Beijing 1.076
Dublin 996
Singapore 976
Fairfield 971
Santa Clara 856
Ashburn 689
Houston 659
Wilmington 560
Torino 539
Woodbridge 475
Redwood City 394
Villeurbanne 394
Seattle 389
Dearborn 344
Medford 343
Princeton 311
Nyköping 307
Cambridge 301
Jacksonville 294
Columbus 290
Vienna 276
Turin 254
Pisa 227
Warsaw 210
Fremont 186
Jakarta 179
Milan 164
Dong Ket 125
New York 122
Boston 103
Guangzhou 97
Helsinki 94
Shanghai 92
San Diego 91
Nuremberg 90
Hangzhou 68
Nanjing 66
Paris 66
Toronto 66
Brussels 64
Boardman 62
São Paulo 62
Rome 55
Washington 55
Taipei 53
Los Angeles 51
Silver Spring 51
Hong Kong 50
Munich 48
Ottawa 48
Phoenix 46
Lima 45
Cape Town 43
London 43
Chicago 42
Hebei 42
Santiago 42
Kunming 40
Seoul 39
Verona 39
Norwalk 37
Barcelona 34
Frankfurt am Main 34
Hefei 33
Amsterdam 32
Chengdu 32
Madrid 31
Omaha 31
Tokyo 31
Bengaluru 30
Brno 29
Buenos Aires 29
Hanoi 27
Montreal 26
Buffalo 25
Falls Church 25
Upper Marlboro 25
Bologna 23
Dallas 23
San Francisco 23
Central District 22
Melbourne 22
Arlington 21
Düsseldorf 21
Minneapolis 21
Wuhan 21
Bangkok 20
Jinan 20
Zhengzhou 20
Changsha 19
Copenhagen 19
Duncan 19
Mumbai 19
Pune 19
Sydney 19
Brescia 18
Montréal 18
Mountain View 18
Totale 20.310
Salva come PNG Salva come JPEG
Nome #
Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization? 829
Pharmacokinetics and pharmacodynamics of antiretrovirals in the central nervous system. 731
Cytomegalovirus central nervous system compartmentalization in a patient presenting with AIDS 616
Cardiac dysfunction in pauci symptomatic human immunodeficiency virus patients: a meta-analysis in the highly active antiretroviral therapy era 513
Antiretroviral therapy in geriatric HIV patients: The GEPPO cohort study 457
TB and COVID-19 co-infection: Rationale and aims of a global study 437
The outcome of HIV-positive late presenters according to detectable CMV DNA and anti-CMV treatment 433
High prevalence at computed coronary tomography of non-calcified plaques in asymptomatic HIV patients treated with HAART: A meta-analysis 400
Cerebrospinal Fluid Inhibitory Quotients of Antiretroviral Drugs in HIV-positive Patients are Associated with Compartmental Viral Control. 394
Elvitegravir/Cobicistat/Tenofovir/Emtricitabine Penetration in the Cerebrospinal Fluid of Three HIV-Positive Patients 356
Effect of SNPs in human ABCB1 on daptomycin pharmacokinetics in Caucasian patients. 347
A UPLC-MS-MS method for the simultaneous quantification of first-line antituberculars in plasma and in PBMCs 336
High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis. 331
Prevalence and predictors of long corrected QT interval in HIV-positive patients: a multicenter study 325
Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms. 324
HIV-1 Very Low Level Viremia is Associated with Virological Failure in HAART-treated Patients 310
Heart failure in patients with human immunodeficiency virus: a review of the literature. 305
Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment. 296
Tenofovir clearance is reduced in hiv-positive patients with subclinical tubular impairment 290
Tenofovir coadministration is not associated with lower unboosted atazanavir plasma exposure in the clinical setting 289
CNS-Targeted Antiretroviral Strategies: When Are They Needed and What to Choose 279
Raltegravir penetration in seminal plasma of healthy volunteers. 260
Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study) 253
SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV 253
Health-care Associated KPC-BSI: The Time Has Come. 252
Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells. 246
Lower dolutegravir plasma concentrations in HIV-positive patients receiving valproic acid 241
Single-nucleotide polymorphisms ABCB1 3435C>T, 1236C>T and CYP2B6 516G>T influence plasma concentrations of Efavirenz (EFV). 236
Presence of EBV DNA in Cerebrospinal Fluid is Associated with Greater HIV RNA and Inflammation 233
Pharmacogenetics of Antiretrovirals' Penetrations into Cerebrospinal Fluid 221
Prevalence and predictors of blood-brain barrier damage in the HAART era. 216
Acute HIV infection: Improved algorithms for HIV testing. 213
Pharmacogenetic determinants of kidney-associated urinary and serum abnormalities in antiretroviral-treated HIV-positive patients 213
SLC28A2 65C>T predict Sustained Virological Response in patients with hepatitis C treated with interferon and ribavirin, considering all HCV genotype and genotype 1/4. 204
Cerebrospinal fluid viral load and neopterin in HIV-positive patients with undetectable viraemia 198
Comparative safety and efficacy of statins for primary prevention in human immunodeficiency virus-positive patients: a systematic review and meta-analysis 196
Anti-CD20 antibody therapy for B-cell lymphomas 195
Could ritonavir intracellular concentrations have a role as active drugs when used as a booster PIs? 190
The Influence of Pharmacogenetic Variants in HIV/Tuberculosis Co-infected Patients in Uganda in the SOUTH Study 190
Cardiovascular disease in HIV patients: from bench to bedside and backwards 187
Effect of Darunavir (DRV) genotypic inhibitory quotient (gIQ) on the virological response to DRV-containing salvage regimens at 24 weeks 186
Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens 185
Elimination half-life may explain the relative efficacy of boceprevir and telaprevir in the treatment of hepatitis C virus genotype 1. 185
In-hospital and long-term outcomes of HIV-positive patients undergoing PCI according to kind of stent: a meta-analysis 185
SLC29A1 −706G>C predict haemoglobin decrease in patients with hepatitis C treated with interferon and ribavirin 181
TENOFOVIR AND EMTRICITABINE CSF-TO-PLASMA RATIOS CORRELATE TO THE EXTENT OF BLOOD BRAIN-BARRIER DAMAGE 179
Clinical pharmacology of tenofovir clearance: a pharmacokinetic/pharmacogenetic study on plasma and urines 179
A filter-based cross-sectional analysis of an HIV-positive, HAART-treated cohort in rural Burundi: pharmacokinetics, pharmacogenetics and viral load 177
A population pharmacokinetic model confirms an association between a pregnane-X-receptor (PXR) polymorphism and unboosted atazanavir clearance 176
A(H1N1)pdm09 hemagglutinin D222G and D222N variants are frequently harbored by patients requiring extracorporeal membrane oxygenation and advanced respiratory assistance for severe A(H1N1)pdm09 infection 176
Plasma and Intracellular Imatinib Concentrations in Patients With Chronic Myeloid Leukemia 176
Etravirine Plasma Exposure is Associated with Virological Efficacy in Treatment-experienced HIV-positive Patients. 175
Symptomatic cerebrospinal fluid HIV-1 escape with no resistance-associated mutations following low-level plasma viremia 174
Analysis of determinants of long-term efficacy of unboosted atazanavir-based regimens in the clinical setting 173
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update December 2014 173
Efficacy, safety and pharmacokinetics of atazanavir (200mg twice daily) plus raltegravir (400mg twice daily) dual regimen in the clinical setting 173
Tuberculosis and COVID-19 co-infection: description of the global cohort 173
Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics. 168
INTRACELLULAR ACCUMULATION OF RITONAVIR ASSOCIATED WITH DIFFERENT BOOSTED PIS 168
Determinants of Tenofovir Plasma Trough Concentrations: a Cross-sectional Analysis in the Clinical Setting 168
Viral rebound after switch to maraviroc/raltegravir dual therapy in highly experienced and virologically suppressed patients with HIV-1 infection. 166
Tenofovir and emtricitabine cerebrospinal fluid-to-plasma ratios correlate to the extent of blood-brainbarrier damage. 163
Pharmacokinetic Determinants of Immunovirological Response in HIV Very Late Presenters 162
Pharmacokinetics of 400 mg of raltegravir once daily in combination with atazanavir/ritonavir plus two nucleoside/nucleotide reverse transcriptase inhibitors. 160
Ribavirin pharmacokinetics and interleukin 28B plus cytochrome P450 27B1 single-nucleotide polymorphisms as predictors of response to pegylated interferon/ribavirin treatment in patients infected with hepatitis C virus genotype 1/4. 159
Undetectable Ritonavir Plasma Concentrations in Different Boosted PI-based Regimens as a Marker of Non-Adherence: analysis of a large TDM Registry 158
Pharmacokinetics of Raltegravir, Etravirine and Maraviroc regimen in the clinical setting 158
Pharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients. 158
Tenofovir Plasma Concentrations According to Companion Drugs: a Cross-sectional Study in HIV-positive Patients with Normal Renal Function. 156
Efficacy, Safety and Pharmacokinetics of Atazanavir (200 mg twice-daily) plus Raltegravir (400 mg twice-daily) Dual Regimen in the Clinical Setting 156
Clinical pharmacology of complex regiment of antiretroviral therapy including Etravirine, Maraviroc and Raltégravir. 156
Single-nucleotide polymorphism PXR 7635G>A influences plasma concentrations of Efavirenz in CYP2B6 516G>T carriers 156
Detectable cerebrospinal fluid JCV DNA in late-presenting HIV-positive patients: beyond progressive multifocal leukoencephalopathy? 155
GREATER IMMUNOLOGICAL RECOVERY ASSOCIATED WITH ADDITIONAL ENFUVIRTIDE IN THE TREATMENT OF NAIVE HIV-INFECTED PATIENTS AT VERY ADVANCED DISEASE STAGES: 24-WEEK RESULTS OF A RANDOMIZED, CONTROLLED, PILOT STUDY 155
Clinically significant drug interaction between tipranavir-ritonavir and phenobarbital in an HIV-infected subject 154
Louseborne relapsing fever among East African refugees, Italy, 2015 154
The symptomatology of cerebrospinal fluid HIV RNA escape: a large case-series 154
MONITORING OF VIROLOGICAL AND PHARMACOLOGICAL CEREBROSPINAL FLUID PARAMETERS IN HAART-TREATED HIV-POSITIVE PATIENTS IN THE CLINICAL SETTING 152
Pharmacokinetic and pharmacodynamic determinants of early virological response to enfuvirtide-based regimens in HIV-positive patients 151
Short-term additional enfuvirtide therapy is associated with a greater immunological recovery in HIV very late presenters: a controlled pilot study. 151
Intracellular accumulation of the new integrase inhibitors elvitegravir and dolutegravir in HIV patients 151
What do we know about tailoring treatment with tenofovir? 151
Dual antiretroviral therapies are effective and safe regimens in the central nervous system of neurologically symptomatic people living with HIV 151
Viral rebound after switch to Maraviroc-Raltegravir dual therapy 150
High incidence of infections in HIV-positive patients treated for lymphoproliferative disorders 150
Comparative evaluation of seven resistance interpretation algorithms and their derived genotypic inhibitory quotients for the prediction of 48 week virological response to darunavir-based salvage regimens. 150
Pharmacokinetics of the Dual NRTI- and Protease Inhibitor-sparing Regimen Raltegravir plus Nevirapine in HIV-1+ Patients 149
Role of vitamin D pathway gene polymorphisms on rifampicin plasma and intracellular pharmacokinetics 147
Steady-state Raltegravir Penetration in Seminal Plasma of Healthy Volunteers 146
High Interpatient Variability of Raltegravir Cerebrospinal Fluid Concentrations in HIV-positive Patients: a Pharmacogenetic Analysis 146
Seminal pharmacokinetics and antiviral efficacy of once-daily maraviroc plus lopinavir/ritonavir in HIV-infected patients. 145
Antiretroviral Drug Penetration into the CNS Compartment 145
Medication Burden and Clustering in People Living with HIV Undergoing Therapeutic Drug Monitoring 143
Genetic Polymorphisms Affecting the Pharmacokinetics of Antiretroviral Drugs 140
Intracellular Pharmacokinetics of Boosted and Unboosted Atazanavir in HIV Infected Patients 139
Etravirine Plasma Exposure is Associated with virological Response in Experienced HIV-positive Patients 139
Is Maraviroc a substrate for SLCO1B1? 138
Antiviral activity of maraviroc plus mirtazapine in a low-risk HIV-negative patient with progressive multifocal leukoencephalopathy 137
Is peritoneal fluid a sanctuary site for HIV? 136
Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial (Journal of Translational Medicine, (2020), 18, 1, (405), 10.1186/s12967-020-02573-9) 136
Totale 22.348
Salva come PNG Salva come JPEG
Categoria #
all - tutte 102.628
article - articoli 0
book - libri 0
conference - conferenze 17.114
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 119.742
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.933 0 0 0 0 0 0 0 0 344 461 512 616
2020/20213.619 459 197 189 210 295 314 246 153 312 291 272 681
2021/20226.028 481 414 510 578 448 451 543 496 376 276 746 709
2022/20235.490 525 409 153 509 515 1.333 375 390 591 147 302 241
2023/20242.797 337 423 181 153 229 385 103 173 59 160 253 341
2024/20254.800 171 385 345 594 1.460 481 241 398 725 0 0 0
Totale 35.840